Graft Versus Host Disease (GVHD)
Transplant and GVHD Session - 2025 Kansas City Patient and Family Conference
Topic(s)
Bone Marrow Transplant
In this recording, Dr. Anurag Singh discusses transplant and potentials complications such as GVHD and treatment options. Recording includes the question-and-answer session.
Living Well with Bone Marrow Failure, from the 2025 Kansas City Patient and Family Conference
Topic(s)
Living Well with Bone Marrow Failure
Managing Your Treatment
In this recording, Dr. Furha Cossor discusses living with bone marrow failure and fatigue management. Recording includes the question-and-answer session.
Urge your Members of Congress to Reverse the 57% Cut to the Congressionally Directed Medical Research Program
Original Publication Date
Article Source
Take Action
Federal budget negotiations are already under way. April 15 marks the 30-Day anniversary of the enactment of the 57% cut to CDMRP including the elimination of all funding to Bone Marrow Failure Research. Every medical research program at CDMRP directly impacts the health and…
AAMDSIF Supports the Accelerating Kids' Access to Care Act
Original Publication Date
Article Source
Coalition Action
AAMDSIF Supports the Accelerating Kids' Access to Care Act. On March 26, 2025, AAMDSIF joined with 212 additional patient advocacy and medical center organizations in urging members of the US Congress to pass the Accelerating Kids’ Access to Care Act. Passage of this bill will…
Make Your Voice Count!
Join us in endorsing the recent appeal to Congress with the following actions. Your voice is important to continue these services for patients and provide opportunities for researchers to find the cures.
Read the letter to Congress from Research!America, with AAMDSIF and 600 other organizations, here.
Letter on the Bipartisan Senate FY25 Labor-HHS-Education Appropriations Bill
Original Publication Date
Article Source
Coalition Action
AAMDSIF is Taking a Stand for NIH Research Research programs led by the National Institutes of Health (NIH) forge the way for life-saving new treatments for rare diseases such as aplastic anemia, MDS, and PNH. With clinical research locations throughout the U.S., researchers and…
FDA Approves Axatilimab in 9 Mg and 22 Mg Vial Sizes for GVHD
Original Publication Date
Article Source
External Web Content
Axatilimab-csfr (Niktimvo), a CSF-1R–targeting agent that reduces the drivers of inflammation and fibrosis, has been approved by the FDA in 9 mg and 22 mg vial sizes to treat adult and pediatric patients with graft-versus-host disease (GVHD), according to a news release from the…